The International Prostate Cancer Group, which was founded through the association of prostate cancer experts from the United States and Europe, has defined its mission: to optimize quality treatment and support services for patients with prostate cancer. The basis are scientific collaboration, information exchange, and patient consultation. The international association was founded by the Directors of the West German Prostate Center and the New York Prostate Cancer Center In June of 2007.
At the center of this cooperation is the coordination and implementation of joined research projects in the area of diagnosis and therapy of prostate cancer, patient consultation, and the continuing education and training for physicians.
Since Guy´s & St. Thomas Hospitals in London and the Urological University Clinic in Basel joined the association in 2008, the IPG is now one research association comprised of the four international institutions with the highest caseload in the area of prostate diseases.
The IPG utilized an international network to take part in scientific studies, and to discuss current research results on a transnational basis. The International Prostate Cancer Group aims to transpose new medical findings into clicincal practice according to today’s needs and demands.
Currently a vast number of effective and proven therapy options for the treatment of prostate cancer are developing. The IPG continuously analyzes and critically compares new and innovative therapies with existing standard therapies.
This means that patients with prostate cancer in Germany and in foreign countries have the opportunity to utilize the medical knowledge of the experts, and to obtain an independent second opinion.